Table 2 Prognostic factors for overall survival, event-free survival and disease relapse (distant or local): univariate analysis

From: Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

  

Overall survival (months)

Event-free survival (months)

Local relapse (months)

Distant metastases (months)

Factor

Characteristics

Median

P

Median

P

Median

P

Median

P

Baseline patient characteristics

 

Overall (months)

35.1

—

14.8

—

29.9

—

18.9

—

 1

Age (⩽59/⩾60 years)

35.1/30.0

0.40

11.6/15.5

0.66

25.2/30.3

0.53

13.0/24.6

0.45

 2

Gender (female/male)

46.1/27.4

0.15

30.3/12.5

0.34

43.3/25.2

0.33

30.3/15.5

0.73

 3

PS (0/1–2)

39.0/34.0

0.54

19.5/13.6

0.95

30.3/29.9

0.44

25.9/14.8

0.72

 4

Smoking (pack-years ⩽45/>45)

39.0/27.4

0.48

14.9/14.8

0.67

31.7/21.2

0.32

21.8/15.5

0.87

 

Smoking (continued/stopped or never)

29.9/39.0

0.96

12.3/21.1

0.56

16.6/42.1

0.22

14.2/24.6

0.45

 5

LDH (⩽1/>1 × ULN)

35.1/21.6

0.49

12.3/13.6

0.49

26.3/25.2

0.46

21.8/14.5

0.72

 6

Haemoglobin (⩽/> 134 g l−1 (median)

29.9/43.8

0.38

13.6/25.2

0.29

26.3/43.4

0.17

15.4/27.4

0.34

Baseline tumour characteristics

 7

Histology (squamous/adenocarcinoma+other)

30.0/39.0

0.75

19.2/12.7

0.10

31.7/26.3

0.55

22.8/15.4

0.08

 8

Tumour stage (T1–2/T3)

27.6/57.1

0.12

13.7/15.5

0.12

26.3/NR

0.14

21.8/15.5

0.40

 9

Differentiation (G1–2/G3)

30.0/46.1

0.69

14.7/14.0

0.58

29.9/26.3

0.98

15.5/18.9

0.73

10

N multilevel (no/yes)

43.4/21.8

0.05

15.5/9.8

0.47

31.7/12.6

0.36

19.5/12.6

0.39

11

N enlargement on CT scan before chemotherapy (⩽1 cm/>1 cm)

32.5/29.9

0.47

8.9/12.7

0.71

18.9/26.3

0.72

9.3/15.4

0.50

Characteristics of the surgery

12

Right pneumonectomy (no/yes)

30.0/46.1

0.56

13.6/26.3

0.36

29.9/26.3

0.58

15.6/40.9

0.27

13

Resection margin of primary tumour (negative/positive)

43.3/16.5

0.10

15.5/11.4

0.11

31.7/15.8

0.07

22.8/12.4

0.04

14

Complete tumour resectiona (yes/no)

62.5/17.3

<0.0001

42.1/9.6

<0.0001

NR/14.4

<0.0001

54.5/13.0

<0.0001

Activity of the chemotherapy

15

Clinical response (CR+PR/NC)

43.8/20.0

0.03

22.8/9.2

0.02

43.3/16.2

0.004

24.6/9.4

0.03

16

Complete pathological response (⩾95%) (no/yes)

28.8/NR

0.04

12.4/62.5

0.008

25.2/NR

0.005

15.4/NR

0.006

17

Pathological response (<60%/⩾60%)

22.4/60.6

0.03

9.0/42.1

<0.0001

16.6/46.9

0.0009

11.7/54.5

<0.0001

18

Mediastinal downstaging (N0/N1/N2)

NR/35.1/16.4

0.0001

42.1/15.8/8.6

0.0003

NR/25.2/14.4

<0.0001

NR/19.5/9.3

0.0003

 

Mediastinal downstaging (N0/N1+N2)

NR/22.1

0.001

42.1/11.4

0.008

NR/17.1

0.001

NR/14.2

0.005

 

Mediastinal downstaging (N0+N1/N2)

57.1/16.4

<0.0001

25.2/8.6

<0.0001

43.8/14.4

<0.0001

26.4/9.3

0.0001

19

Uppermost mediastinal lymph node involved (no/yes)

62.5/17.3

<0.0001

39.4/9.2

<0.0001

46.9/14.4

<0.0001

43.2/12.2

<0.0001

  1. CR=complete response; CT=computed tomography; LDH=lactate dehydrogenase; N=node; NC=no change; NR=median value not reached; P=log-rank test P-value; PD=progressive disease; PR=partial response; PS=performance status; ULN=upper limit of normal.
  2. aComplete tumour resection: negative resection margin and no involvement of the uppermost mediastinal lymph node.
Back to article page